Commercial PrEP Prescriptions in the U.S.: 2012–2018

Over the initial 7-year period since PrEP became available in the U.S., prescriptions to commercially insured patients increased steadily but remained disappointingly low.

Since the approval in 2012 of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) by the FDA for use in preexposure HIV infection prophylaxis (PrEP), numerous additional studies and clinical experience have demonstrated its effectiveness when taken regularly. For this study, researchers evaluated use of ≥30 days of TDF/FTC for PrEP according to the 2012–2018 MarketScan Commercial and Medicare Supplemental database, excluding persons with HIV or hepatitis B virus infection. Prescriber information (when available) was categorized as primary care, infectious disease, or other specialties. Starting in 2015, when unique identifiers were available, prescribers were further categorized as HIV providers (those who prescribed medications to person…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Commercial PrEP Prescriptions in the U.S.: 2012–2018

Topics

Reviewing Author